Published in Microb Cell Fact on September 12, 2005
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Bacterial inclusion bodies contain amyloid-like structure. PLoS Biol (2008) 1.63
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact (2009) 1.59
Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol (2006) 1.20
Active protein aggregates induced by terminally attached self-assembling peptide ELK16 in Escherichia coli. Microb Cell Fact (2011) 1.16
Inclusion bodies: a new concept. Microb Cell Fact (2010) 1.16
Engineering inclusion bodies for non denaturing extraction of functional proteins. Microb Cell Fact (2008) 1.16
Enzyme clustering accelerates processing of intermediates through metabolic channeling. Nat Biotechnol (2014) 1.11
Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact (2010) 1.09
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
Physiological aggregation of maltodextrin phosphorylase from Pyrococcus furiosus and its application in a process of batch starch degradation to alpha-D-glucose-1-phosphate. J Ind Microbiol Biotechnol (2007) 0.94
The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol (2008) 0.94
Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microb Cell Fact (2012) 0.92
Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb Cell Fact (2015) 0.90
Modeling amyloids in bacteria. Microb Cell Fact (2012) 0.87
Small surfactant-like peptides can drive soluble proteins into active aggregates. Microb Cell Fact (2012) 0.86
Active protein aggregates produced in Escherichia coli. Int J Mol Sci (2011) 0.86
Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microb Cell Fact (2012) 0.86
A Structural Study of CESA1 Catalytic Domain of Arabidopsis Cellulose Synthesis Complex: Evidence for CESA Trimers. Plant Physiol (2015) 0.85
Components of the E. coli envelope are affected by and can react to protein over-production in the cytoplasm. Microb Cell Fact (2009) 0.85
Self-assembling, protein-based intracellular bacterial organelles: emerging vehicles for encapsulating, targeting and delivering therapeutical cargoes. Microb Cell Fact (2011) 0.85
Active inclusion bodies of acid phosphatase PhoC: aggregation induced by GFP fusion and activities modulated by linker flexibility. Microb Cell Fact (2013) 0.84
Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol (2009) 0.84
Combinatorial mutagenesis and selection of improved signal sequences and their application for high-level production of translocated heterologous proteins in Escherichia coli. Appl Environ Microbiol (2012) 0.84
Why and how protein aggregation has to be studied in vivo. Microb Cell Fact (2013) 0.83
Inclusion bodies as potential vehicles for recombinant protein delivery into epithelial cells. Microb Cell Fact (2012) 0.83
Influence of production process design on inclusion bodies protein: the case of an Antarctic flavohemoglobin. Microb Cell Fact (2010) 0.83
Size characterization of inclusion bodies by sedimentation field-flow fractionation. J Biotechnol (2008) 0.83
Simple genetic selection protocol for isolation of overexpressed genes that enhance accumulation of membrane-integrated human G protein-coupled receptors in Escherichia coli. Appl Environ Microbiol (2010) 0.82
Expanding the recombinant protein quality in Lactococcus lactis. Microb Cell Fact (2014) 0.81
Formation of active inclusion bodies induced by hydrophobic self-assembling peptide GFIL8. Microb Cell Fact (2015) 0.80
Two distinct states of Escherichia coli cells that overexpress recombinant heterogeneous β-galactosidase. J Biol Chem (2012) 0.80
A variant of green fluorescent protein exclusively deposited to active intracellular inclusion bodies. Microb Cell Fact (2014) 0.78
Prokaryotic ubiquitin-like ThiS fusion enhances the heterologous protein overexpression and aggregation in Escherichia coli. PLoS One (2013) 0.78
Screening and identification of genetic loci involved in producing more/denser inclusion bodies in Escherichia coli. Microb Cell Fact (2013) 0.78
Controlled localization of functionally active proteins to inclusion bodies using leucine zippers. PLoS One (2014) 0.78
Bacterial inclusion bodies as potential synthetic devices for pathogen recognition and a therapeutic substance release. Microb Cell Fact (2013) 0.77
Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microb Cell Fact (2011) 0.77
Activation of alpha chymotrypsin by three phase partitioning is accompanied by aggregation. PLoS One (2012) 0.77
Synonymous rare arginine codons and tRNA abundance affect protein production and quality of TEV protease variant. PLoS One (2014) 0.77
Methyl alpha-D-glucopyranoside enhances the enzymatic activity of recombinant beta-galactosidase inclusion bodies in the araBAD promoter system of Escherichia coli. J Ind Microbiol Biotechnol (2008) 0.77
Disulfide bond formation and activation of Escherichia coli β-galactosidase under oxidizing conditions. Appl Environ Microbiol (2012) 0.77
Mammalian prion protein (PrP) forms conformationally different amyloid intracellular aggregates in bacteria. Microb Cell Fact (2015) 0.77
Functional inclusion bodies produced in the yeast Pichia pastoris. Microb Cell Fact (2016) 0.76
Use of a stress-minimisation paradigm in high cell density fed-batch Escherichia coli fermentations to optimise recombinant protein production. J Ind Microbiol Biotechnol (2014) 0.76
The effects of protein solubility on the RNA Integrity Number (RIN) for recombinant Escherichia coli. Biochem Eng J (2013) 0.75
Artificially designed recombinant protein composed of multiple epitopes of foot-and-mouth disease virus as a vaccine candidate. Microb Cell Fact (2017) 0.75
The scientific impact of microbial cell factories. Microb Cell Fact (2008) 0.75
Stabilization of a prokaryotic LAT transporter by random mutagenesis. J Gen Physiol (2016) 0.75
Application of an E. coli signal sequence as a versatile inclusion body tag. Microb Cell Fact (2017) 0.75
Morphological differences between β(2) -microglobulin in fibrils and inclusion bodies. Chembiochem (2011) 0.75
The effect of protein acetylation on the formation and processing of inclusion bodies and endogenous protein aggregates in Escherichia coli cells. Microb Cell Fact (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol (1999) 11.38
Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol (1999) 6.98
Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol (2004) 4.47
Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact (2005) 2.67
Kinetic partitioning of protein folding and aggregation. Nat Struct Biol (2002) 2.37
Amyloid-like properties of bacterial inclusion bodies. J Mol Biol (2005) 1.90
Nativelike secondary structure in interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR. Biochemistry (1994) 1.67
Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry (1990) 1.66
Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins. Microb Cell Fact (2004) 1.64
Protein aggregation as bacterial inclusion bodies is reversible. FEBS Lett (2001) 1.52
Characterization of the aggregates formed during recombinant protein expression in bacteria. BMC Biochem (2005) 1.38
High activity of inclusion bodies formed in Escherichia coli overproducing Clostridium thermocellum endoglucanase D. FEBS Lett (1991) 1.35
Fine architecture of bacterial inclusion bodies. FEBS Lett (2000) 1.28
Factors influencing inclusion body formation in the production of a fused protein in Escherichia coli. Appl Environ Microbiol (1991) 1.23
The formation of biologically active beta-galactosidase inclusion bodies in Escherichia coli. Aust J Biotechnol (1989) 1.17
Optimized release of recombinant proteins by ultrasonication of E. coli cells. Biotechnol Bioeng (1998) 1.14
Kinetics of inclusion body formation studied in intact cells by FT-IR spectroscopy. FEBS Lett (2005) 1.08
Folding of a misfolding-prone beta-galactosidase in absence of DnaK. Biotechnol Bioeng (2005) 1.01
Improving heterologous protein folding via molecular chaperone and foldase co-expression. Methods Mol Biol (2003) 1.01
Cysteine to serine substitutions in basic fibroblast growth factor: effect on inclusion body formation and proteolytic susceptibility during in vitro refolding. Biotechnology (N Y) (1992) 0.99
Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem Biophys Res Commun (2004) 0.85
Variable specific activity of Escherichia coli beta-galactosidase in bacterial cells. Biotechnol Bioeng (2001) 0.84
AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics (2007) 3.02
Protein quality in bacterial inclusion bodies. Trends Biotechnol (2006) 2.02
Amyloid-like properties of bacterial inclusion bodies. J Mol Biol (2005) 1.90
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact (2009) 1.59
Prediction of "hot spots" of aggregation in disease-linked polypeptides. BMC Struct Biol (2005) 1.34
The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng (2007) 1.34
Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J Am Chem Soc (2009) 1.32
Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer's peptide. Side-chain properties correlate with aggregation propensities. FEBS J (2006) 1.29
Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc Natl Acad Sci U S A (2005) 1.25
Inclusion bodies: specificity in their aggregation process and amyloid-like structure. Biochim Biophys Acta (2008) 1.24
Amyloids in bacterial inclusion bodies. Trends Biochem Sci (2009) 1.24
Recombinant protein solubility - does more mean better? Nat Biotechnol (2007) 1.21
Protein aggregation: mechanisms and functional consequences. Int J Biochem Cell Biol (2012) 1.20
Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol (2006) 1.20
Simplified, enhanced protein purification using an inducible, autoprocessing enzyme tag. PLoS One (2009) 1.19
Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol (2007) 1.18
Role of molecular chaperones in inclusion body formation. FEBS Lett (2003) 1.16
Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol (2005) 1.12
Recent structural and computational insights into conformational diseases. Curr Med Chem (2008) 1.12
Prion and non-prion amyloids of the HET-s prion forming domain. J Mol Biol (2007) 1.11
Protein folding and aggregation in bacteria. Cell Mol Life Sci (2010) 1.10
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact (2010) 1.09
A coupled protein and probe engineering approach for selective inhibition and activity-based probe labeling of the caspases. J Am Chem Soc (2013) 1.09
Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol (2009) 1.08
Folding of small disulfide-rich proteins: clarifying the puzzle. Trends Biochem Sci (2006) 1.07
Bacterial inclusion bodies: making gold from waste. Trends Biotechnol (2011) 1.07
Amyloid fibril formation by a partially structured intermediate state of alpha-chymotrypsin. J Mol Biol (2004) 1.06
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv (2012) 1.05
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Effect of temperature on protein quality in bacterial inclusion bodies. FEBS Lett (2006) 1.05
Protein activity in bacterial inclusion bodies correlates with predicted aggregation rates. J Biotechnol (2006) 1.02
Detection of transient protein-protein interactions by bimolecular fluorescence complementation: the Abl-SH3 case. Proteomics (2007) 1.02
AGGRESCAN: method, application, and perspectives for drug design. Methods Mol Biol (2012) 1.01
Bacterial inclusion bodies of Alzheimer's disease β-amyloid peptides can be employed to study native-like aggregation intermediate states. Chembiochem (2011) 1.01
Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J (2011) 1.01
Folding of a misfolding-prone beta-galactosidase in absence of DnaK. Biotechnol Bioeng (2005) 1.01
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology (2010) 1.00
Prediction of the aggregation propensity of proteins from the primary sequence: aggregation properties of proteomes. Biotechnol J (2011) 0.99
Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng (2008) 0.99
NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol (2013) 0.98
Study and selection of in vivo protein interactions by coupling bimolecular fluorescence complementation and flow cytometry. Nat Protoc (2008) 0.96
Nanostructured bacterial materials for innovative medicines. Trends Microbiol (2010) 0.95
Discovering putative prion sequences in complete proteomes using probabilistic representations of Q/N-rich domains. BMC Genomics (2013) 0.95
Characterization of the amyloid bacterial inclusion bodies of the HET-s fungal prion. Microb Cell Fact (2009) 0.95
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases. PLoS Comput Biol (2009) 0.94
The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol (2008) 0.94
Sulfated polysaccharides promote the assembly of amyloid beta(1-42) peptide into stable fibrils of reduced cytotoxicity. J Biol Chem (2008) 0.93
Ile-phe dipeptide self-assembly: clues to amyloid formation. Biophys J (2006) 0.93
Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation. Mol Biosyst (2012) 0.92
Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microb Cell Fact (2012) 0.92
Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure. FASEB J (2010) 0.91
Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol (2008) 0.91
The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials (2010) 0.90
Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microb Cell Fact (2012) 0.90
Protein aggregation profile of the bacterial cytosol. PLoS One (2010) 0.90
PrionScan: an online database of predicted prion domains in complete proteomes. BMC Genomics (2014) 0.90
Evolutionary selection for protein aggregation. Biochem Soc Trans (2012) 0.89
Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol (2011) 0.89
Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater (2012) 0.89
Yeast prions form infectious amyloid inclusion bodies in bacteria. Microb Cell Fact (2012) 0.88
Modular protein engineering for non-viral gene therapy. Trends Biotechnol (2004) 0.88
Studies on bacterial inclusion bodies. Future Microbiol (2008) 0.88
Linking amyloid protein aggregation and yeast survival. Mol Biosyst (2011) 0.88
Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. J Biotechnol (2005) 0.87
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) (2010) 0.87
Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. Biochem Biophys Res Commun (2007) 0.87
Modeling amyloids in bacteria. Microb Cell Fact (2012) 0.87
The in vivo and in vitro aggregation properties of globular proteins correlate with their conformational stability: the SH3 case. J Mol Biol (2008) 0.87
Protein complementation assays: approaches for the in vivo analysis of protein interactions. FEBS Lett (2009) 0.87
Insertional protein engineering for analytical molecular sensing. Microb Cell Fact (2006) 0.87
Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem (2004) 0.86
Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett (2007) 0.86
Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. Biotechnol Prog (2010) 0.86
Scrambled isomers as key intermediates in the oxidative folding of ligand binding module 5 of the low density lipoprotein receptor. J Biol Chem (2008) 0.86
Modular protein engineering in emerging cancer therapies. Curr Pharm Des (2009) 0.86
Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol Adv (2009) 0.86
Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem Biophys Res Commun (2004) 0.85